Latest Share Purchase Plan News

RBR Group Limited is strategically positioning itself to capitalise on the restart of major LNG projects in Mozambique, advancing joint ventures and raising capital to meet anticipated demand.

Astute Metals has reported its highest-grade lithium intersections to date at the Red Mountain Project in Nevada, alongside promising beneficiation testwork and new gold-silver exploration targets at the Needles Project.

EQ Resources delivered a robust Q4 FY2025 with strong tungsten output from its Spanish and Australian operations, bolstered by strategic capital raises and key plant enhancements.

Prescient Therapeutics has raised nearly $10 million through a placement and share purchase plan to advance its promising PTX-100 targeted cancer therapy into pivotal clinical stages.

Greenwing Resources reports solid progress across its lithium and graphite assets in Argentina, Madagascar, and Tasmania, completing a $3.5 million equity raise and appointing a new chairman.

Astute Metals NL has successfully raised $5.5 million through an oversubscribed placement to advance its Nevada lithium and gold projects, including a maiden resource estimate and new drilling campaigns.

Aguia Resources reported steady progress in its June 2025 quarter, highlighting underground gold production in Colombia and development milestones in Brazil’s phosphate project, alongside strategic capital raises and operational restructuring.

Imugene Limited reports strong clinical progress with its off-the-shelf CAR T therapy azer-cel achieving a 75% overall response rate in Phase 1b trials, alongside new patents and leadership appointments. The company also secured $22.5 million in fresh funding to advance pivotal trials.

Beetaloo Energy Australia Limited has completed a $35 million capital raise and successfully finished hydraulic stimulation of its Carpentaria-5H well, setting the stage for production expected in 2026. Traditional Owner consent and strong liquidity underpin the company’s next development phase.

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.

Turaco Gold has reported a significant 40% increase in its Afema Project gold resource to 3.55 million ounces, alongside promising high-grade drilling results and a robust $60 million capital raise to fund ongoing development.

Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.